Free Republic

WASHINGTON — Researchers must go back to the drawing board before they can develop an effective vaccine against H.I.V., AIDS experts said at a scientific meeting on Tuesday. And Dr. Anthony S. Fauci, the top federal official responsible for AIDS research, agreed that more fundamental knowledge is needed about H.I.V. and the way the body and experimental vaccines respond to it before the goal of a licensed H.I.V. vaccine can be reached. Dr. Fauci, the director of the National Institute of Allergy and Infectious Diseases, pledged to re-evaluate the use of all $1.5 billion his agency spends on AIDS research...

BOSTON--Two prominent researchers have bluntly assessed the depressing state of AIDS vaccine research and have urged the U.S. National Institutes of Health (NIH) to correct its course. In back-to-back plenary talks at the 15th Conference on Retroviruses and Opportunistic Infections today, Ronald Desrosiers, director of the New England Primate Research Center in nearby Southborough, said he thought that NIH--the world's largest funder of AIDS vaccine research--had "lost its way," spending too much money on developing and testing products and not enough on basic research. Virologist Neal Nathanson, a professor emeritus at the University of Pennsylvania who formerly headed NIH's Office...

Six volunteers have received a cocktail of China's experimental AIDS vaccines, signalling a new phase in the country's quest to find an indigenous remedy to fight the deadly disease which is spreading rapidly, the state media reported on Sunday. After receiving medical check-ups, the six volunteers were inoculated with the vaccines in Nanning, capital of south China's Guangxi Zhuang Autonomous Region, on Saturday. The volunteers will receive another three injections in the coming three months, the director of the Guangxi Disease Prevention and Control Centre, Chen Jie, said. The latest round of AIDS vaccine research was launched after a two-month...

<p>VaxGen's experimental AIDS vaccine couldn't block HIV infection among volunteers in Thailand, the Brisbane company said Wednesday, in another blow for the closely scrutinized drug.</p> <p>The vaccine, dubbed AIDSVAX, had no noticeable effect on infection rates among the 2,546 intravenous drug users in Bangkok who volunteered for the study. Nor did it slow the disease's progress among volunteers who took the vaccine and later contracted HIV.</p>